<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00457275</url>
  </required_header>
  <id_info>
    <org_study_id>0653-070</org_study_id>
    <secondary_id>2007_012</secondary_id>
    <nct_id>NCT00457275</nct_id>
  </id_info>
  <brief_title>Observational Study to Evaluate LDL-C Lowering Effect of Ezetimibe (0653-070)</brief_title>
  <official_title>A Multicentre, Open-Label, Observational Local Study to Evaluate the LDL-C Lowering Effect of Ezetimibe as Prescribed in Daily Routine Practice in the South African Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      To evaluate the LDL-C lowering in south african patients with primary hypercholesterolaemia
      after the addition of ezetimibe 10mg /day to ongoing therapy with a statin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Approval</measure>
  </primary_outcome>
  <enrollment>440</enrollment>
  <condition>Hypercholesterolemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK0653, ezetimibe / Duration of Treatment: 4 Weeks</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women &gt;18 and &lt;80 years of age

          -  Patients receiving statin therapy for a minimum period of 6 weeks prior to visit 1

          -  Female patients receiving hormone therapy (including hormone replacement therapy, any
             estrogen antagonist/agonist, or oral contraceptives) if maintained on a stable dose
             and regimen for at least 8 weeks prior to visit 1 and if willing to continue the same
             regimen throughout the study

          -  Liver enzyme levels less than or equal to 1.5 times the upper limit of normal with no
             active liver disease and CPK less than or equal to 1.5 times upper limit of normal at
             visit 1

        Exclusion Criteria:

          -  Cardiovascular medications, such as beta-blockers, calcium-channel blockers,

        angiotensin ii receptor antagonists or anticoagulants (i.e., warfarin) unless

        treated with a stable regimen for at least 6 weeks prior to randomization and

        patient agrees to remain on constant regimen for the duration of the study

          -  Patients on amiodarone hydrochloride will also be excluded

          -  General weight less than 50% of ideal body weight according to the 1983 metropolitan
             height and weight tables or weighing less than 100 lbs (45 kg)

          -  Hypersensitivity to HMG-COA reductase inhibitors

          -  Patient has congestive heart failure defined by nyha class III or IV, uncontrolled
             cardiac arrhythmias, unstable angina pectoris, or myocardial infarction; coronary
             artery bypass surgery, or angioplasty within 3 months of visit 1

          -  Taking lipid-lowering agents including fish oils, cholestin, bile-acid sequestrants

        and niacin (grater than 200 mg/day) taken within 6 weeks and fibrates taken within 8 weeks
        prior to visit 1

          -  Taking medications that are potent inhibitors of cyp3a4, including cyclosporine,

        systemic itraconazole or ketoconazole, erythromycin or clarithromycin,

        nefazodone, verapamil and protease inhibitors

          -  Consumption of greater than 250 ml of grapefruit juice/day

          -  Taking oral corticosteroids unless used as replacement therapy for pituitary/adrenal
             disease and on a stable regimen for at least 6 weeks prior to visit 1

          -  Treatment with psyllium, other fiber-based laxatives, and/or OTC therapies

        known to affect serum lipid levels, phytosterol margarines, unless treated with

        a stable regimen for at least 6 weeks prior to visit 1 and patient agrees to remain on
        constant regimen for the duration of the study

          -  Women who are pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <results_reference>
    <citation>Raal F, Schamroth C, Patel J, Becker P. A multicentre, open-label, observational local study to evaluate the low-density lipoprotein cholesterol-lowering effect of ezetimibe as prescribed in daily routine practice in the South African population. Cardiovasc J Afr. 2007 Sep-Oct;18(5):325-9.</citation>
    <PMID>17985033</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2007</study_first_submitted>
  <study_first_submitted_qc>April 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2007</study_first_posted>
  <last_update_submitted>March 7, 2017</last_update_submitted>
  <last_update_submitted_qc>March 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis Link</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

